By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



29 Emmons Drive
Suite C-10
Princeton  New Jersey  08540  U.S.A.
Phone: 609-538-8200 Fax: 609-452-6467


Company News
Soligenix (SNGX) Enters Into A $10 Million Equity Purchase Agreement 8/3/2015 6:31:37 AM
Soligenix (SNGX) Announces Collaboration With The National Organization for Rare Disorders And The Cutaneous Lymphoma Foundation In Advancing Its Phase 3 Study Of SGX301 For The Treatment Of Cutaneous T-Cell Lymphoma 6/23/2015 7:15:29 AM
Soligenix (SNGX) Announces Publication Of Successful Application Of Its Heat Stabilization Technology To A Human Papillomavirus Vaccine 6/2/2015 6:15:33 AM
Soligenix (SNGX) Announces Collaboration With The University Of Hawai'i At Manoa And Hawaii Biotech To Develop Heat Stable Ebola Vaccine 5/28/2015 6:24:49 AM
Soligenix (SNGX) Announces First Quarter 2015 Highlights And Financial Results 5/14/2015 10:38:43 AM
Soligenix (SNGX) Announces Development Agreement With Emergent BioSolutions (EBS) 5/13/2015 6:40:15 AM
Soligenix (SNGX) Announces Presentation And Poster At The 2015 Chemical And Biological Defense Science And Technology Conference In St. Louis, MO 5/4/2015 12:23:18 PM
Soligenix (SNGX) Announces FDA Protocol Clearance Of Pivotal Phase 3 Clinical Trial Of SGX203 In Pediatric Crohn's Disease 4/14/2015 6:13:36 AM
Soligenix (SNGX)'s CEO Christopher Schaber Interviewed By The Life Sciences Report 4/10/2015 1:35:43 PM
DSG, Inc. Partners With Soligenix (SNGX) To Battle Cutaneous T-Cell Lymphoma 4/7/2015 10:41:14 AM